The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across the globe, including in areas where the PURPOSE trials were conducted.
Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Associate Professor of Medicine (AIDS) and of Pharmacology, Yale
Principal investigator, PURPOSE 2
Articles by Onyema Ogbuagu, MBBCh, FACP, FIDSA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5